Abstract
Introduction
The occurrence of depression during pregnancy is a frequent situation that must be distinguished from postpartum depression. It raises many questions regarding its complications and therapeutic options.Objectives
To provide a systematic review of available data on prevalence, risk factors, and adverse outcomes of antepartum depression, as well as on screening tools and treatments currently available.Methods
Studies, reviews, and meta-analyses were searched through the Pubmed and Embase databases. Articles related to postpartum depression or specifically focusing on bipolar disorder were excluded.Results
Epidemiology
Prevalence is estimated between 5 and 15%. Risk factors, in addition to those of any depression, are an ambivalent attitude towards pregnancy, previous miscarriages, and medically-assisted or complicated pregnancies. Diagnosis and screening: No specific tool has yet been designed to diagnose or screen antepartum depression, but some scales (EPDS, PRIME-MD PHQ) have been validated. Adverse outcomes: For the mother, adverse outcomes are those of any depression, in addition to an increased risk of delivery complications and of postpartum depression. For the child, there is an increased risk for preterm birth, low birth-weight, and possibly sudden death.Treatments
- Tricyclic antidepressants are widely described as safe during pregnancy. SSRIs show much reassuring data, even though recent studies have raised concerns about cardiac malformations and persistent pulmonary hypertension of the newborn. Electroconvulsive therapy is only indicated in the most severe cases but appears secure under specific safety measures. Most psychotherapies have not been specifically assessed during pregnancy. Other treatments (bright light therapy, rTMS…) have shown some promising but not robust results.Conclusion
Antepartum depression is frequent, and potentially severe if not treated. Validation of specific screening tools is warranted. Pharmacological treatment should not be postponed in cases of severe depression. Regarding moderate depressions, it appears reasonable to turn to non-pharmacological treatments, primarily psychotherapies, which therefore should be more thoroughly studied.References
Articles referenced by this article (103)
Validation of the Edinburgh Postnatal Depression Scale as a screening tool for depression in late pregnancy among Nigerian women.
J Psychosom Obstet Gynaecol, (4):267-272 2006
MED: 17225628
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
Am J Psychiatry, (5):592-606 1996
MED: 8615404
American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006;108:1601–3.
American Psychiatric Association. DSM IV, texte révisé.
American Psychiatric Association. Assessing and treating suicidal behaviours; 2003.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2nd ed.; 2000.
American Psychiatric Association Committee Electroconvulsive Therapy. Recommendations for treatment, training, and privileging (A task force report of the American Psychiatric Association). 2nd ed. American Psychiatric Association; 2001.
Depression and anxiety during pregnancy and six months postpartum: a follow-up study.
Acta Obstet Gynecol Scand, (8):937-944 2006
MED: 16862471
Neonatal outcome following maternal antenatal depression and anxiety: a population-based study.
Am J Epidemiol, (9):872-881 2004
MED: 15105180
Use of antidepressant medications during pregnancy: a multisite study
Am J Obstet Gynecol, e1- 2008
Show 10 more references (10 of 103)
Citations & impact
Impact metrics
Citations of article over time
Article citations
Duloxetine Exposure During Pregnancy and the Risk of Offspring Being Born Small for Gestational Age or Prematurely: A Nationwide Danish and Swedish Safety Study.
Drugs Real World Outcomes, 10(1):69-81, 10 Nov 2022
Cited by: 0 articles | PMID: 36355315 | PMCID: PMC9943795
Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden.
PLoS Med, 18(11):e1003851, 22 Nov 2021
Cited by: 5 articles | PMID: 34807906 | PMCID: PMC8654175
Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study.
Drugs Real World Outcomes, 8(3):289-299, 18 May 2021
Cited by: 5 articles | PMID: 34008161 | PMCID: PMC8324661
Psycho-educational interventions focused on maternal or infant sleep for pregnant women to prevent the onset of antenatal and postnatal depression: A systematic review.
Neuropsychopharmacol Rep, 41(1):2-13, 19 Dec 2020
Cited by: 6 articles | PMID: 33340291 | PMCID: PMC8182965
Review Free full text in Europe PMC
Predicting Postpartum Depressive Symptoms from Pregnancy Biopsychosocial Factors: A Longitudinal Investigation Using Structural Equation Modeling.
Int J Environ Res Public Health, 17(22):E8445, 14 Nov 2020
Cited by: 8 articles | PMID: 33202688 | PMCID: PMC7696025
Go to all (24) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Antepartum and postpartum depression.
J Gend Specif Med, 1(2):33-36, 01 Oct 1998
Cited by: 10 articles | PMID: 11281010
Review
[Depression during pregnancy].
Ther Umsch, 67(11):571-575, 01 Nov 2010
Cited by: 3 articles | PMID: 21043017
Review
Using the Patient Health Questionnaire (PHQ-9) and the Edinburgh Postnatal Depression Scale (EPDS) to assess suicidal ideation among pregnant women in Lima, Peru.
Arch Womens Ment Health, 18(6):783-792, 05 Nov 2014
Cited by: 39 articles | PMID: 25369907 | PMCID: PMC4635023
The prevalence of perinatal depression and its associated factors in two different settings in Brazil.
J Affect Disord, 136(3):1204-1208, 12 Dec 2011
Cited by: 43 articles | PMID: 22169251